Newly Developing IgM Anti‐ GD1a / GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

ABSTRACT Background and Aims Chronic inflammatory demyelinating neuropathy (CIDP) is a rare, immune‐mediated neuropathy that is distinct from other immune‐mediated, paraneoplastic, and paraproteinemic neuropathies that may have overlapping clinical features. Identification of the specific diagnosis in each patient is important as each of these disorders has distinct pathophysiology and treatment response. Case Report Here, we present an atypical case of CIDP in which the patient developed an IgM monoclonal gammopathy with positive anti‐ganglioside antibodies over 20 years into his disease course. Interpretation Patients with CIDP may be predisposed to develop IgM autoantibodies or monoclonal gammopathies. If a patient with CIDP experiences clinical worsening while on maintenance therapy, it may be helpful to test for anti‐ganglioside antibodies and monoclonal gammopathies and reassess if alternative treatment would be useful.

Authors

Institutions

Publication Details

Journal
Journal of the Peripheral Nervous System
Published
2026-09-24
DOI
https://doi.org/10.1111/jns.70174
Primary Topic
Peripheral Neuropathies and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Newly Developing IgM Anti‐ GD1a / GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Norman Latov, Jennifer A. Langsdorf, Ruby Ross
Journal of the Peripheral Nervous System
Peripheral Neuropathies and Disorders
article

Newly Developing IgM Anti‐ GD1a / GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Norman Latov, Jennifer A. Langsdorf, Ruby Ross
article en

Abstract

ABSTRACT Background and Aims Chronic inflammatory demyelinating neuropathy (CIDP) is a rare, immune‐mediated neuropathy that is distinct from other immune‐mediated, paraneoplastic, and paraproteinemic neuropathies that may have overlapping clinical features. Identification of the specific diagnosis in each patient is important as each of these disorders has distinct pathophysiology and treatment response. Case Report Here, we present an atypical case of CIDP in which the patient developed an IgM monoclonal gammopathy with positive anti‐ganglioside antibodies over 20 years into his disease course. Interpretation Patients with CIDP may be predisposed to develop IgM autoantibodies or monoclonal gammopathies. If a patient with CIDP experiences clinical worsening while on maintenance therapy, it may be helpful to test for anti‐ganglioside antibodies and monoclonal gammopathies and reassess if alternative treatment would be useful.

Journal of the Peripheral Nervous SystemVol. 31(4)
Cornell University (US)
Good health and well-being
Openalex Percentile: Top 11%
Peripheral Neuropathies and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.